Program
Chorionic Gonadotropin
Also written as “hCG”, “HCG injection” and “Pregnyl: Human chorionic gonadotrophin”.
Its studies are mostly in Hypogonadism · Infertility · Infertility, Female, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 20 open or running | phase 3since Oct 16, 2012 | Oct 16, 2012 | none ahead |
| Fertility Center of Las Vegas | 11 open or running | phase 4since May 27, 2025 | May 27, 2025 | Dec 31, 2027phase 4 · NCT07004192 |
| Genuine Research Center, Egypt | 10 open or running | phase 4since Sep 22, 2020 | Sep 22, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2012First study: phase 3 study in HypogonadismNew to OrganonOrganon · NCT01709331 · 18 enrolled
- Jan 11, 2017Phase 3 study in HypogonadismOrganon · NCT03019575 · 17 enrolled · Brazil, Denmark, Italy and more
- Sep 22, 2020Genuine Research Center, Egypt's first study: phase 4 study in Infertility, FemaleNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04605107 · 60 enrolled · Egypt
- May 27, 2025Fertility Center of Las Vegas's first study: phase 4 study in InfertilityNew to Fertility Center of Las VegasFertility Center of Las Vegas · NCT07004192 · 220 planned · United States
Ahead
- Dec 31, 2027Primary completion: phase 4 study in InfertilityFertility Center of Las Vegas · NCT07004192
TargetBeta
“Luteinizing hormone/Choriogonadotropin receptor agonist”ChEMBL 37, by rule
Other programs on LHCGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutropin alfarule | Merck KGaA, Darmstadt, Germany | phase 4 | 9 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07004192Infertility · United States | 4 | Recruiting | Fertility Center of Las Vegas | Dec 31, 2027 | 220 |
| NCT04605107Infertility, Female · Egypt | 4 | Completed | Genuine Research Center, Egypt | Jan 8, 2015 | 60 |
| NCT03019575Hypogonadism · Brazil, Denmark, Italy and more | 3 | Completed | Organon | May 5, 2020 | 17 |
| NCT01709331Hypogonadism | 3 | Completed | Organon | Apr 8, 2015 | 18 |
How it is read
Names in the registry
- “hCG”, 2 entries
- “HCG injection”, 1 entry
- “Pregnyl: Human chorionic gonadotrophin”, 1 entry
Conditions, from the studies’ own filings
- Hypogonadism, 2 studies
- Infertility, 1 study
- Infertility, Female, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.